

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026910 A1

(51) International Patent Classification⁷: C07K 16/12, 16/40, 7/08

(21) International Application Number:
PCT/IN2002/000192

(22) International Filing Date:
20 September 2002 (20.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): LUPIN LTD [IN/IN]; 159, CST Road, Kalina, Santacruz (East), Mumbai 400 098, Maharashtra (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NAGARAJA, Valakunja [INRN]; Department of Microbiology & Cell Biology, Indian Institute of Science, Bangalore 560 012,

Karnataka (IN). MANJUNATHA, Ujjini, Havaladar [INRN]; Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560 012, Karnataka (IN). ROY, Bhairab, Nath [INRN]; Lupin Ltd (Research Park), 46A/47A, Nande Village, Taluka Mulshi, Pune 411 02, Maharashtra (IN).

(74) Agents: SUBRAMANIAM, Hariharan et al.; Subramaniam, Nataraj & Associates, E-556, Greater Kailash-II, New Delhi 110 048 (IN).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: MONOCLONAL ANTIBODY DERIVED PEPTIDE INHIBITORS FOR MYCOBACTERIAL DNA GYRASE

1 - GCCCAGGTGAAACTGCAGCAGTCTGGGGCTGAATTTGGTGAGGCCTGGGGCTTCAGTG - 60
A Q V K L Q Q S G A E L V R P G A S V K
61 - TTGTCTGCAAGGCTTCTGGCTACAGCTTCACCGTCTACTATATTTACTGGGTGAAACAG - 120
L S C K A S G Y S F T V Y Y I Y W V K Q
121- AGGCCTGGCAAGCCCTTGAGTGGATTGGAGAGATTAATCCTAGCAATGGTGGTACTAAC - 180
R P G Q A L E W I G E I N P S N G G T N
181- TTCAATGAAAAGTTCAAOCACCAAGGCCACTGACTGTAGACAAATCCACCAGCAGATC - 240
F N E K F K T K A T L T V D K S T S T V
241- TACATGCAACTCAGCAGCCTGACATCTGAAGACTCTGCGGTCTATTACTGTAC - GAT - 300
Y M Q L S S L T S E D S A V Y Y C T R W
301- GOGTTACULCWLGGOTTGCTTACTGGGGCCAAGGGGAC - CGGTCCACCGTCTCCTCAAGT - 360
- G L R R G F A Y W G Q G T T V T V S S S
361- GGAGCGGTTCAAGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACATCGAGCTCACTCAG - 420
G G G S G G G G S G G G G S D I E L T Q
421- TCTCCAAATCCATGTCATGTAGTAGGAGAGAGGGTACCTTGAAGTGCAGGCCAGT - 480
S P K S M S M S V G E R V T L S C K A S
481- WL~TGTGGTACTCATGTATCCTGGTATCAAGCAGAGACAGAGGAGTCTCCT - CTG 540
E N V G T R V S W Y Q Q R P E E S P K L
541- CTGATATACOOOOCATCCAACCOOTA - CTGGGGTCCCCGATCGCTTACAGGCAGTGGC - 600
L I Y G A S N R Y T G V P D R F T G S G
601- TCTGCAACAGATTTCACTCTGACCATCAGCAATGTGTGACAGGCTG - GACCTTGCA - TTAF 660
S A T D F T L T I S N V Q A E D L A D Y
661- CACTGTGGACAGACTTACAGCTATCCATTACATTCGGCTTGGGGACAAAGTGGAAATA - 720
H C G Q T Y S Y P F T F G L G T K L E I
721- AAACGGGCGCCGAGGTGCGCGGTGCCGTATCCGGATCCGGTGAACCGCGTCCGCA - 780
K R A A A G A P V P Y P D P L E P R A A
781- TAG - 783

(57) Abstract: The present invention relates to the development of monoclonal antibodies that specifically inhibit DNA gyrase from *M. tuberculosis*, *M. smegmatis* and possibly from other related bacterial species. More particularly, it has been shown that the inhibition of the enzyme is by a hitherto unknown and novel mechanism. The present invention also relates to a DNA sequence of single chain antibody consisting of complementarity determining regions of mAb. The monoclonal antibody, single chain antibody and peptides derived thereof could be useful for developing lead molecules for tuberculosis therapy. The antibodies and derived materials could be useful for a variety of purposes, including diagnosis of mycobacterial infections. The present invention also relates to the modification of antibodies and derived materials for use against diverse microbial infections and other potential applications derived thereof.

WO 2004/026910 A1



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, **MR**, **NE**, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

MONOCLONAL ANTIBODY DERIVED PEPTIDE INHIBITORS FOR MYCOBACTERIAL DNA GYRASE

The present invention provides a monoclonal antibody (mAb), an engineered single chain antibody (scFv), peptides carrying complementarity determining regions (CDR) and peptides derived from CDRs and framework regions, all of which specifically inhibit mycobacterial DNA gyrase activity.

BACKGROUND OF THE INVENTION

Mycobacterium tuberculosis, the causative agent of tuberculosis is responsible for millions of deaths worldwide each year. One third of the global population is infected with tuberculosis with 6 million new cases reported every year. 20% of adult deaths and 6% of infant deaths are attributable to tuberculosis (C. Dye et. al., *J. Am. Med. Ass.*, 1999, 282, 677-686). The synergy between tuberculosis and the AIDS epidemic, and the emergence of multi-drug-resistant strains of *M. tuberculosis* has resulted in the urgent need for new drugs to combat *M. tuberculosis* infections (S. H. E. Kaufmann et. al., *Trends Microbiol.*, 1993, 1, 2-5 ; B. R. Bloom et. al., *N. Engl. J. Med.*, 1998, 338, 677-678).

DNA gyrase is an essential topoisomerase, found exclusively in bacteria. The enzyme belongs to the family of type II DNA topoisomerases, a group of enzymes that catalyze interconversions of different DNA topological forms. The enzyme is a chosen molecular target for the development of new antibacterials due to its ability to supercoil DNA, a property not shared by other topoisomerases (A. Maxwell, *Trends Microbiol.*, 1997, 5, 102-109 ; J. J. Champoux, *Annu. Rev. Biochem.*, 2001, 70, 369-413 ; A. D. Bates et. al., In DNA topology, Oxford University Press, Oxford, 1993; R. J. Reece et. al., *CRC Crit. Rev. Biochem Mol. Biol.*, 1991, 26, 335-375).

The DNA gyrase has been extensively studied from *E. coli*. The enzyme from *E. coli* is composed of two subunits, DNA gyrase A protein (GyrA) and DNA gyrase B protein (GyrB), the active form being an A₂B₂ heterotetramer. GyrA comprises two domains; an N-terminal domain (64 kDa) that contains the active-site tyrosine residue involved in DNA cleavage, and C-terminal domain that is involved in the wrapping of a segment of DNA around A₂B₂ complex. The GyrB protein also consists of two domains: a 43 kDa N-terminal domain, containing the site of ATP binding and hydrolysis, whereas 47 kDa C-terminal domain is involved in DNA binding and interaction with GyrA subunit (R. J. Reece et. al., *CRC Crit. Rev. Biochem. Mol. Biol.*, 1991, 26, 335-375).

A large number of *E. coli* DNA gyrase inhibitors, which belong to diverse classes, have been characterized. Amongst them, quinolones and coumarins were the first ones to be characterized and most extensively studied for their inhibitory activity.

The quinolones are synthetic class of compounds, which interfere with the processes of rejoining the double strand breaks in DNA (K. Drlica et. al., *Biochemistry*, **1988**, 27, 2253-2259). New generation of quinolones especially fluoroquinolones have found wide applications clinically for variety of bacterial infections (D. C. Hooper, *Emerg Infect Dis.*, **2001**, 7, 337-41). Although mycobacteria have been found to be naturally less susceptible to quinolones than other bacteria (J. S. Wolfson et. al., *Clin. Microbiol. Rev.*, **1989**, 2, 378-424), new quinolones have been demonstrated to be active against mycobacterial infections (J. M. Woodcock et. al., *Antimicrobial. Agents Chemother.*, **1997**, 41, 101-116). Amongst them moxifloxacin and sparfloxacin have been found to be most active against mycobacteria (S. H. Gillespie et. al., *J. Antimicrob. Chemother.*, **1999**, 44, 393-395 ; U. H. Manjunatha et. al., *Nucleic Acids Res.*, **2002**, 30, 2144-2153).

The coumarins are naturally occurring antibiotics, which affect ATPase activity of gyrase (H. Hoeksema et. al., *J. Am. Chem. Soc.*, **1985**, 78, 6710-6711; R. J. Lewis et. al., *EMBO J.*, **1996**, 15, 1412-1420). Cyclothialidines, a class of cyclic peptides have been characterized to inhibit DNA gyrase activity in a fashion analogous to that of coumarins (N. Nakada et. al., *Antimicrob. Agents Chemother.*, **1994**, 38, 1966-1973). In addition, two proteinaceous poisons, microcin B17 (F. Baquero et. al., *J. Bacteriol.*, **1978**, 135, 342-347) and CcdB (P. Bernard et. al., *J. Mol. Biol.*, **1992**, 226, 735-745) inhibit *E. coli* DNA gyrase. Most of these characterized inhibitors fall into two groups based on their site of action and mechanism of inhibition, one that affects cleavage-rejoining step and others that inhibit ATP hydrolysis. Supercoiling reaction involves a series of complicated steps, yet the inhibitors described target only two of these steps.

The present invention is based on the premise that the enzyme provides additional opportunities to develop inhibitors, which could affect other steps in the reaction cycle. The potential inhibition of other steps of gyrase reaction has not been explored so far.

Considering the global menace of mycobacterial infections the approach adapted by our laboratory has been to study mycobacterial gyrase and compare its properties with the well-characterized DNA gyrase for development of a mycobacterial enzyme as molecular target for new drug discovery.

For this purpose GyrA and GyrB subunits from *M. smegmatis* (K. Madhusudan et. al., *Microbiology*, 1995, 140, 3029-3037) and *M. tuberculosis* (K. Madhusudan et. al., *Biochem. Mol. Biol. Int.*, 1994, 33, 651-660 ; U. H. Manjunatha et. al., *Curr. Sci.*, 2000, 78, 968-974) have been cloned and over-expressed. The studies on mycobacterial DNA gyrase and comparison of its properties with *E. coli* enzyme has revealed many differences, leading to the classification of DNA gyrases into two subclasses (U. H. Manjunatha et. al., *Curr. Sci.*, 2000, 78, 968-974 ; M. Ghatteji, et. al., *J. Biol. Chem.*, 2000, 275, 22888-22894 ; U. H. Manjunatha et. al., *Eur. J. Biochem.*, 2001, 268, 2038-2046). Unlike *E. coli* enzyme, mycobacterial gyrase is refractory to the plasmid borne proteinaceous inhibitors CcdB and microcin B17 and exhibits reduced susceptibility to fluoroquinolones (M. Chatterji et. al., *J. Antimicrob. Chemother.*, 2001, 48, 479-485 ; U. H. Manjunatha et. al. *Nucleic Acids Res.*, 2002, 30, 2144-215).

Monoclonal antibodies owing to their specificity of interaction have been exploited in biology for variety of purposes leading to various applications. They are routinely used in diagnostics, structure-function analysis and as reagents to study protein-protein interactions. A more recent application is the identification of peptide inhibitors for potential antigens by paratope derived peptide approach. R. B. Tournaire et. al., (*EMBO J.*, 2000, 19, 1525-1533) have identified a peptide that blocks vascular endothelial growth factor (VEGF) mediated angiogenesis, using an anti-WGF mAb. However, development of neutralizing monoclonal antibodies and design of peptide inhibitors against mycobacterial DNA gyrase is an approach not been carried out for any other topoisomerases.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides an engineered single chain antibody, viz. a recombinant ScFV : GyraA protein, which inhibits DNA gyrase from *M. smegmatis* and *M. tuberculosis*.

In another aspect, the present invention provides a plasmid encoding the recombinant ScFV : GyraA protein, viz. pVNUHMScFv, which inhibits DNA gyrase from *M. smegmatis* and *M. tuberculosis*.

In yet another aspect, the present invention provides a DNA sequence of the plasmid encoding the recombinant ScFV : GyraA protein as shown in Seq. ID # 1, which inhibits DNA gyrase from *M. smegmatis* and *M. tuberculosis*.

In yet another further aspect, the present invention provides an amino acid sequence of the recombinant ScFV : GyraA protein as shown in Seq. ID # 2, which inhibits DNA gyrase from *M. smegmatis* and *M. tuberculosis*.

In yet another embodiment of the invention, said engineered single chain antibody contains an amino acid sequences which inhibit the activity of DNA gyrase from *M. smegmatis* and *M. tuberculosis*, said amino acid sequences having the Seq. ID # 3 and Seq. ID # 4 respectively.

In a further aspect, the present invention provides monoclonal antibodies, viz. MSGyrA:C3 and MSGyrA:H11, which inhibits DNA gyrase from fluoroquinolone resistant *M. szegzatis* and *M. tuberculosis*.

In yet another further aspect, the present invention provides hybridoma cell lines C3B3 and H11E1, which secrete the monoclonal antibodies, MSGyrA:C3 and MSGyrA:H11, which also inhibits DNA gyrase from *M. szegzatis* and *M. tuberculosis*.

The monoclonal antibody (mAb) described in this invention has been generated against GyrA subunit of *M. smegmatis* DNA gyrase. The mAb cross reacts with GyrA subunit from fast and slow growing mycobacteria (U. H. Manjunatha et. al., *Eur. J. Biochem.*, **2001**, 268, 2038-2046). The invention describes the inhibition of DNA supercoiling activity catalyzed by *M. smegmatis* and *M. tuberculosis* DNA gyrases by full-length mAb and its Fab and single chain antibody (scFv) fragments. The present invention also describes inhibition of DNA gyrase activity by peptides derived fi-om scFv. The invention also deals with novel mechanism of DNA gyrase inhibition is distinct from that of other known DNA gyrase inhibitors.

DESCRIPTION OF THE FIGURES

Figure 1A : Specificity of interaction of mAb.

Figure 1B : Effect of mAbs on mycobacterial DNA gyrase supercoiling activity.

Figure 2A : Effect of MsGyrA:C3 on DNA binding.

Figure 2B : Effect of MsGyrA:C3 on DNA cleavage.

Figure 2C : Effect of MsGyrA:C3 on ATP hydrolysis.

Figure 2D : Effect of MsGyrA:C3 on ATP independent DNA relaxation reaction of mycobacterial DNA gyrase.

Figure 3A and 3B : Effect of MsGyrA:C3 on quinolone resistant *M. smegmatis* DNA gyrase.

Figure 3C : Effect of MsGyrA:C3 on quinolone resistant *M. tuberculosis* DNA gyrase.

Figure 3D : Effect of MsGyrA:H11 on quinolone resistant *M. smegmatis* DNA gyrase.

5 **Figure 4A** : Surface plasmon resonance spectroscopy showing affinity of interaction of scFv:GyrA with GyrA as compared to that of IgG or Fab fragments.

Figure 4B : Comparison of the inhibition of *M. smegmatis* DNA supercoiling activity of scFv:GyrA polypeptide and IgG or Fab fragments.

Figure 4C : Effect of scFv:GyrA on *M. tuberculosis* DNA gyrase.

10 **Figure 5**: Nucleotide and predicted amino acid sequences of scFv:GyrA gene;

Figure 6 : Peptide sequences of the engineered single chain antibody, scFv:GyrA and the effect of paratope derived peptides, CDR:H1 and CDR:H3 on *M. smegmatis* DNA gyrase supercoiling activity.

15 **Figure 7** : Effect of scFv:GyrA and CDR:peptides on ciprofloxacin resistant *M. smegmatis* DNA gyrase supercoiling activity.

DETAILED DESCRIPTION OF THE INVENTION

The DNA supercoiling activity is essential for bacterial survival. The invention pertains to development of monoclonal antibodies (mAb) and its single chain antibody (ScFv) to neutralize mycobacterial DNA gyrase supercoiling activity. The mAb henceforth is termed as MsGyrA:C3 and its single chain antibody fragment is referred as scFv:GyrA. The other mAb described in the present invention is MsGyrA:H11. The monoclonal antibodies can be obtained from culture supernatant of the secreting hybridoma cell line in the tissue culture medium or from the ascitic fluid by injecting hybridoma cells into the peritoneal cavity of mouse. The mAb can be purified by protein-
20 A or protein-G sepharose affinity column or by any other chromatographic techniques. The antigen binding fragments of mAb can be obtained by papain or pepsin digestion of
25 IgG or other methods.

The present invention provides opportunities for utilization of DNA gyrase as drug target by employing novel strategies. The polypeptide inhibitor (mAbs) characterized here selectively inhibits DNA gyrase from *M. smegmatis* and *M. tuberculosis*. Since mAb cross-reacts with GyrA from other species of mycobacteria (*M. bovis*, *M. leprae* and *M. avium*; U. H. Manjunatha et. al., *Eur. J. Biochem.*, **2001**, 268, 2038-2046), it opens up the avenue for the design of specific lead molecules targeted against other mycobacterial infections, The present investigation brings to the fore the

distinct mechanism of DNA gyrase inhibition by mAb from that of quinolone or coumarin class of drugs, Absence of cross-resistance to fluoroquinolone resistant DNA gyrase by mAb, warrants the pursuit of this strategy further as it could aid in countering the drug resistance problem. In addition, these novel inhibitors could an invaluable tool
5 in elucidating the various steps of supercoiling reaction, which in turn would facilitate rational design of lead molecules.

The invention described includes scFv:GyrA gene sequence encompassing complementarity determining regions (CDRs) as well as framework regions of both heavy and light chains regions. The scFv gene sequence can be obtained by sequencing
10 cDNA from the mAb secreting hydridoma cell line. The scFv polypeptide in the invention was cloned in phagemid vector and expressed on the surface of phages as well as soluble protein. The scFv can also be cloned in other bacterial expression or any other eukaryotic expression system. In the present investigation scFv was cloned with E-tag and the tag specific antibody is used as an affinity handle. Similarly, scFv can be further
15 cloned with or without other polypeptide tags that can be used for purification and detection of the scFv. The scFv illustrated in the present invention can be modified by site directed or random mutagenesis to increase the affinity of interaction or to alter the specificity of interaction by standard molecular biological techniques. The scFv can be expressed in Mycobacterium sp. using suitable expression system to understand the *in*
20 *vivo* role of DNA gyrase and to analyze *in vivo* toxicity of mAb.

The binding strategy utilized by mAbs can be analyzed to develop synthetic peptides with similar binding properties. This has been accomplished in a number of systems where synthetic peptides have been derived directly from the amino acid sequences of CDRs and demonstrated to have binding properties similar to those of the
25 intact antibody. This strategy provides analysis of intermolecular interactions involved in binding and can lead to development of novel binding moieties with predictable activities. A further embodiment of this invention includes design and synthesis of a mimetic from the CDR of an antibody having gyrase inhibitory activity. The peptides could be covalently modified for stability and efficacy. The present invention also
30 includes futuristic design and synthesis of non-peptido mimetics against DNA gyrase derived from paratope derived peptides. Further, the invention can also be used to develop inhibitors with broad-spectrum applications. In a further embodiment of this invention, this approach of developing peptide inhibitors can be used for other topoisomerases as a therapeutic strategy.

The mAb or fragments of antibody described in the invention can also be used as an affinity handle for purification of mycobacterial DNA gyrase. The specificity of interaction of monoclonal antibody and its derivatives to mycobacterial GyrA subunit could also be explored as potential diagnostic reagents for mycobacterial infections. The mAb fragment can be humanized by replacing murine constant regions with human constant regions. The mAbs described in the invention and their fragments can be used to study gyrase interacting proteins, which could be potential drug targets.

The invention is further described in detail as under :

A. Antibody production and characterization

The following experiments were performed to generate *M. smegmatis* GyrA specific mAbs and to study the specificity of interaction and cross-reactivity pattern.

A1 :Generation of anti-GyrA monoclonal antibodies :

To raise monoclonal antibodies (G. Kohler et. al., *Nature*, **1975**, 256, 495-497) against *M. smegmatis* GyrA, 8 weeks old Balb/c mice were immunized with 100 µg GyrA in Freund's complete adjuvant in multiple subcutaneous sites. Mice were boosted at three weekly intervals in incomplete adjuvant for a period of three months, and the immune response was monitored by ELISA using *M. smegmatis* GyrA coated microtiter (Nunc) plates. The spleenocytes from an immunized mouse were fused with Sp2/o myeloma cell line (1:5 ratio) by the PEG-mediated cell fusion technique. The fused cells were selected in HAT medium. The production of antibodies by the clones was assayed by ELISA with the culture supernatant. The clones with consistent and significant reactivity were subcloned to monoclonality by limiting dilution. Two hybridoma clones C3B3 and H11E1 which secrete MsGyrA:C3 and MsGyrA:H11 respectively were further characterized.

A2 :Purification of mAbs:

Hybridoma cells (1×10^6) were washed with serum free medium two times and injected in mice intraperitoneally without priming the animals. The ascitic fluid was collected from animals after 15-18 days of injection. Ascitic fluid was diluted in start buffer containing 3 M NaCl and 1.5 M Glycine-NaOH pH 8.9, and passed through a protein A Sepharose column previously equilibrated with the same buffer (E. Harlow et. al., "*Antibodies :A Laboratory Manual.*" Cold Spring Harbor, New York, **1988**). The elution was done with 100 mM Citrate buffer (elution buffer) (pH 6.0), where IgG₁

elutes at pH 6.0-7.0. The eluate was neutralized immediately with 1.0M Tris-HCl pH 9.0 (neutralizing buffer). The affinity column was regenerated using 100 mM citrate buffer pH 3.0.

5 **A3 -Immunoblotting techniques:**

SDS-PAGE was performed using 8% polyacrylamide separating gels (U. K. Laemmli, *Nature*, **1970**, 227, 680-685). Proteins from the gel were transferred to PVDF membrane in Western transfer buffer (Tris-Cl 25 mM (pH 8.0), Glycine 192 mM and Methanol 20%) for 2 hours at 200 mA using Bio-Rad protein transfer apparatus. The
10 membrane was blocked with 0.4% BSA in PBS, followed by incubation of primary antiserum in PBST-BSA (0.4%) for 2 hours, Bound antibody was detected using an anti-rabbit or anti-mouse horse radish peroxidase conjugate and detected by enhanced chemiluminiscence (Amersham ECL Plus) according to the manufacturer's instructions.

15 **A4 : Experiments to show that mAb is specific to mycobacteria:**

Western Blot analysis using MsGyrA:C3 was performed with purified *M. smegmatis*, *M. tuberculosis* and *E. coli* GyrA proteins. The antibody recognized mycobacterial GyrA subunit but not from *E. coli* (Figure 1A). *M. tuberculosis* and *M. smegmatis* GyrA show proteolytic degradation to a protein fragment of 78 kDa, which
20 was also recognized by the monoclonal antibody. Similar cross-reactivity pattern is observed with another monoclonal antibody MsGyrA:H1 1.

Sequence alignment of *M. smegmatis* GyrA; X84077 (K. Madhusudan et. al., *Microbiology*, **1995**, 140, 3029-3037) with other known mycobacterial DNA GyrA subunits (*M. tuberculosis*; L275 12, H. E. Takiff et. al., *Antimicrob. Agents Chemother.*,
25 **1994**, 38,773-780) and *M. leprae*; Q57532, H. Fsihi et. al., *Proc. Natl. Acad. Sci. USA*, **1996**, 93, 3410-3415) indicates approximately 90% .sequenceidentity at the amino acid level (U. H. Manjunatha et. al., *Curr. Sci.*, **2000**, 78, 968-9). To study the cross-reactivity of the mAbs with gyrases from other mycobacterial species, crude cell lysates were prepared and analyzed by Western Blotting. MsGyrA:C3 recognized GyrA from
30 both fast growing and slow growing mycobacterial species (Figure 1A). The GyrA subunits of all the species tested have very similar molecular weight. As can be seen from Fig. 1A, (i) shows SDS-PAGE and (ii) shows Western blot analysis of purified GyrA proteins (1µg/lane). The protein samples were subjected to SDS-PAGE and Western blot was probed with 10ng/ml of MsGyrA:C3. Fig 1A (iii) shows Western blot

analysis of various slow and fast growing mycobacterial cell free extracts (20µg/lane) with MsGyrA:C3. The size of the GyrA sub-unit is indicated and Mr represents protein size markers with indicated molecular mass.

5 **B. Inhibition of mycobacterial DNA gyrase supercoiling activity**

The experiments presented in this section describe the effect of MsGyrA:C3 and MsGyrA:H11 IgG and their Fab fragments on DNA gyrase supercoiling activity.

B1 : Preparation of Fab fragments:

10 Fab fragments of the IgG were prepared by digestion of the purified IgG with papain. Briefly, 500 µg of purified IgG was incubated in 100 mM sodium acetate buffer, pH 5.5 containing 10 mM β-mercaptoethanol, 1 mM EDTA and 5 µg of papain. Digestion was continued for 12 hours at 37°C in vacuum and quenched by the addition of 150 mM iodoacetamide. The mixture was dialyzed against PBS, purified by protein-A
15 column and analyzed for digestion by 15% SDS-PAGE.

B2 :DNA supercoiling assays:

Relaxed DNA was prepared by treating supercoiled pUC18 DNA with *E. coli* topoisomerase I (R. M. Lyn et. al., *Proteins*, **1989**, 6, 231-239). The supercoiling
20 reaction was carried out in a potassium glutamate buffer (KGB) with 2 mM MgCl₂, 1.8 mM spermidine-HCl, 9 µg/ml yeast t-RNA, 50 µg/ml BSA and 1.4 mM ATP in a 20 µl reaction volume with 300 ng of relaxed DNA. After one hour incubation at 37°C, the reaction was stopped by adding 4 µl of stop buffer (0.6% SDS, 0.2% Bromophenol blue, 0.2% Xylene cyanol FF) and heat inactivated at 75°C for 15 minutes. The samples were
25 electrophoresed in a 1.2% agarose gel for 10-12 hours at 25 V. The gel was stained with ethidium bromide (0.5 µg/ml). The supercoiling assays with *E. coli* gyrase were carried out as described by K. Mizuuchi et. al., *J. Biol. Chem.*, **1984**, 259, 9199-9201. One unit of gyrase was defined as concentration of enzyme that catalyses the conversion of 300 ng of relaxed pUC18 DNA into completely supercoiled form in 1 hour at 37°C.

30

B3 -Experiments to show that mAbs inhibit DNA gyrase supercoiling activity:

M. smegmatis gyrase was preincubated with individual mAbs to allow the formation of the antigen-antibody complex. The mixture was then added to relaxed

pUC18 DNA, in supercoiling reaction buffer. The results (Figure 1B) showed that both MsGyrA:C3 and MsGyrA:H11 inhibited the mycobacterial DNA gyrase supercoiling activity while another mAb MsGyrA:E9 showed no reduction in supercoiling activity. MsGyrA:E9 is also a *M. smegmatis* GyrA specific mAb, interacts with GyrA in a denatured form (U. H. Manjunatha et. al., *Eur. J. Biochem.*, **2001**, 268, 2038-2046).
5 None of these mAbs affected the supercoiling activity of *E. coli* DNA gyrase. This is in agreement with Western Blotting results that had indicated the absence of cross reactivity with the *E. coli* enzyme.

As whole IgG was used in these studies, it was possible that inhibition of gyrase
10 activity resulted from steric effects caused by the Fc regions of these mAbs or by cross-linking of adjacent gyrase molecules. To address this possibility, Fab fragments of mAbs were prepared and tested to determine whether these monovalent fragments were also capable of inhibiting DNA gyrase supercoiling activity. As shown in Figure 1B, Fab fragments of MsGyrA:C3 and MsGyrA:H11 also inhibited the supercoiling reaction.
15 MsGyrA:C3 completely inhibited supercoiling activity at a concentration of 10 nM of IgG and 50 nM of Fab, whereas MsGyrA:H11 whose affinity is slightly lower than MsGyrA:C3 inhibited supercoiling activity completely at a concentration of 50 nM of IgG and 100nM of Fab.

20 **C. Elucidation of mechanism of DNA gyrase inhibition by MsGyrA:C3**

DNA gyrase catalyses inter-conversion of DNA topological forms involving a series of conformational changes in the enzyme. The processes involves the wrapping of DNA around the enzyme, cleavage of DNA in both strands (making a covalent complex of gyrase-DNA), and passage of the segment of DNA through this double strand break.
25 This is coupled to ATP hydrolysis and results in the introduction of negative supercoils (J. J. Champoux, *Annu. Rev. Biochem.*, **2001**, 70, 369-413 ; J. C. Wang, *Annu. Rev. Biochem.*, **1996**, 65, 635-692 and references cited therein). The molecular gates open-close alternatively to ensure that DNA entry-breakage-reunion-exit cycle is completed. This section elucidates the mechanism of DNA gyrase inhibition by the monoclonal
30 antibody. The experiments presented for understanding the mode of mAb inhibition are not routine. MsGyrA:C3 inhibited DNA gyrase activity by a mechanism distinct from that of quinolone and coumarin class of inhibitors. Further, it is demonstrated that the enzyme is inhibited at a novel step of the reaction cycle.

C1 :Purification of DNA gyrase:

M. smegmatis and *M. tuberculosis* DNA gyrase holoenzymes were purified by novobiocin-Sepharose column as described by U. H. Manjunatha et. al., *FEMS Microbiol. Letters*, **2001**, 194, 87-92. Individual mycobacterial gyrase subunits used for
5 some experiments were purified by immunoaffinity column chromatography (U. H. Manjunatha et. al., *Nucleic Acids Res.*, **2002**, 30,2144-2153).

C2 : Electrophoretic mobility shift assay:

Electrophoretic mobility shift assays were carried out using a radiolabeled 240 bp
10 DNA fragment encompassing the strong gyrase site from pBR322 (L. M. Fisher et. al., *Proc. Natl. Acad. Sci. US*", **1981**, 78, 4165-4169). Labeled DNA (0.1×10^{-9} M) was incubated with 5 nM mycobacterial gyrase in supercoiling buffer for 30 minutes at 4 °C. For supershift assays, 5 nM of antibody was added either to enzyme or DNA-enzyme complex. The samples were electrophoresed on a 3.5% native polyacrylamide gel at 4 °C
15 in 0.5 x TBE buffer containing 10 mM MgCl₂.

C3 :ATPase assay:

ATPase assays were performed as described previously by M. Chatterji et. al., *J. Biol. Chem.*, **2000**, 275, 22888-22894 with 10 Us of purified *M. smegmatis* DNA gyrase
20 with or without preincubation of 120 µg/ml mAb or normal mouse IgG or 20 µg/ml novobiocin at 4°C for 30 minutes.

C4 :Cleavage and religation assay:

The cleavage reaction (12.5 µl) was carried out in supercoiling buffer with linear
25 radiolabeled 240 bp DNA fragment with varying concentrations of DNA gyrase in presence of $30 \mu\text{g ml}^{-1}$ ciprofloxacin as described by U. H. Manjunatha et. al., *Nucleic Acids Res.*, **2002**, 30, 2144-2153. The samples were analyzed on 6% denaturing polyacrylamide gel electrophoresis.

C5 :DNA relaxation assay;

Relaxation assays were carried out with 10 U of enzyme in the supercoiling
30 buffer devoid of ATP using supercoiled DNA as substrate and incubated for 6 hours at 37°C.

C6 : Experiments to show that the mechanism of DNA gyrase inhibition by MsGyrA:C3 is distinct from quinolone and coumarin class of inhibitors

The experiments presented in this section of the invention address the mechanism of inhibition of DNA gyrase activity by mAb. We demonstrate that the mAb binding did not affect gyrase subunit-subunit interaction or holoenzyme-DNA interaction. Instead, a ternary complex of gyrase-DNA-mAb is formed (Figure 2A). The ternary complex is competent to perform quinolone induced DNA cleavage (Figure 2B). Further, religation of the cleaved G-segment is also not affected. The conformational changes induced in the quinolone stabilized cleavable complex (S. C. Kampranis et. al., *J. Biol. Chem.*, **1998**, 273, 22606-22614) did not affect mAb binding. In the presence of mAb, trapping of cleaved DNA complex was not observed, implying that the mechanism of inhibition by mAb is distinct from that of quinolone class of drugs.

Binding of mAb to mycobacterial gyrase did not abolish DNA stimulated ATP hydrolysis indicating that mAb mediated inhibition employs distinct mechanism than coumarin class of inhibitors (Figure 2C). Binding of MAb:C3 IgG to gyrase abolishes the ATP independent relaxation of negatively supercoiled DNA (Figure 2D). Similar results were observed with Fab fragments of the mAb as well. Unlike coumarins that inhibit only the supercoiling reaction and not DNA relaxation activity, mAb inhibited both DNA supercoiling as well as DNA relaxation activities, re-emphasizing the distinct mode of mAb action.

D. Inhibition of quinolone resistant *M. smegmatis* and *M. tuberculosis* DNA gyrase by MsGyrA:C3 and MsGyrA:H11

Since the inhibition by mAb is by a mechanism very different from known modes of inhibition, DNA gyrase from quinolone resistant strain should be susceptible to antibody mediated inhibition. In this section, the above hypothesis is tested using quinolone resistant *M. smegmatis* and *M. tuberculosis* DNA gyrases.

D1 : Experiments to show that mAb is effective against quinolone resistant mycobacterial DNA gyrase

DNA gyrase from ciprofloxacin resistant (MIC₅₀ 64 µg/ml) *M. smegmatis* mc²155 strain was used for the experiments. As expected, the enzyme from quinolone sensitive strain showed an IC₅₀ of ~5 µg/ml of ciprofloxacin, whereas resistant strain showed no inhibition even at 400 µg/ml (Figure 3A). DNA supercoiling activity was

inhibited at 3 $\mu\text{g/ml}$ and 6 $\mu\text{g/ml}$ concentrations of MsGyrA:C3 for quinolone sensitive (D^S) and quinolone resistant (D^R) enzymes respectively (Figure 3B). The twofold difference in the mAb concentration between D^S and D^R enzymes is attributed to reduced specific activity of D^R enzyme. DNA gyrase from ofloxacin resistant, highly virulent clinical isolate of *M. tuberculosis* (ICC-222) was also assayed for the effect of mAb. The purified enzyme has an IC_{50} of $\sim 10 \mu\text{g/ml}$ for ciprofloxacin, whereas the MsGyrA:C3 inhibited DNA gyrase supercoiling activity at 3.0 $\mu\text{g/ml}$, similar to that of *M. smegmatis* enzyme (Figure 3C). The absence of cross-resistance essentially emphasizes the mode of action of mAb to be distinct to that of quinolones. Similar to MsGyrA:C3, MsGyrA:H11 also inhibited ciprofloxacin resistant *M. smegmatis* DNA gyrase (Figure 3D). These data confirm the novel inhibition mechanism of gyrase by mAb. Absence of cross-resistance to fluoroquinolone resistant DNA gyrase by mAb, warrants the study of MsGyrA:C3 further as it could aid in countering the drug resistance problem.

15 **E. Cloning, sequencing and expression of a DNA sequence coding for neutralizing antibody gene and design of bioactive peptides**

This example describes the cloning and expression of a nucleic acid sequence coding for a DNA gyrase neutralizing monoclonal antibody, MsGyrA:C3. Based on the inhibition of gyrase by scFv:GyrA and utilizing sequence of the antibody, bioactive peptides were designed and their inhibition of mycobacterial DNA gyrase was tested.

E1 -Cell culture and Isolation of RNA:

Total RNA was isolated from the actively secreting mAb:C3 hybridoma cell line. Briefly, confluent hybridoma cells (3×10^8) were washed with ice cold IMDM medium and total RNA was extracted using TRIzol reagent (Life technologies Inc). RNA was purified using RNeasy QUIAGEN as per the manufacturer's protocol. The quality of RNA was confirmed by electrophoresis in a 1% formaldehyde agarose gel.

E2 -First-strand cDNA synthesis:

30 The first-strand cDNA was synthesized from total RNA using the reverse transcription reaction (RT). For annealing, 5 μg of total RNA was incubated with 0.2 $\mu\text{g/ml}$ of random hexamer oligonucleotide in a 10 μl reaction volume at 70°C for 5 minutes, followed by immediate chilling on ice. The annealed mix was incubated with 1 mM dNTP and 20 Units of Moloney Murine Leukemia Virus reverse transcriptase, (M-

MuLV RT obtained from MBI Fermentas) in RT reaction buffer. The reaction was carried out at 25°C for 10 minutes followed by 37°C for one hour and then stopped by heat denaturation at 70°C for 10 minutes.

5 **E3 -Construction of the scFv gene fragment:**

The single chain Fv of MsGyrA:C3 was cloned using the Recombinant Phage Antibody System (RPAS, Amersham Pharmacia Biotech) as per manufacturer's instructions. The VH and VL antibody genes were amplified in two separate reactions using specific mixture of heavy chain primers and light chain (κ) specific primers with
10 Taq DNA polymerase. The heavy chain amplification reaction yielded a fragment approximately 340 base pairs in length, while the corresponding light chain fragment was 325 base pairs. The gel purified heavy and light chain fragments were assembled into a single gene using a DNA linker fragment. The assembly reaction ultimately produced a small amount of the single-chain Fv gene where the VH region was linked to
15 the VL region via a sequence encoding a (Gly₄Ser)₃ linker. The scFv DNA fragment was -750 base pairs in length. The assembled antibody scFv DNA fragment was amplified by PCR with a set of oligonucleotide primers that introduced Sfi I and Not I sites for cloning into the pCANTAB 5 E vector. The scFv gene product was subsequently cloned in the Not I and Sfi I sites of the pCANTAB 5E phagemid vector (Amersham Pharmacia
20 Biotech) to obtain pVNUHMscFv.

E4 -Expression and Selection of phage scFv:

A recombinant phage antibody library for MsGyrA:C3 was generated by transformation of *E. coli* TG-1 cells with pVNUHMscFV as described above. Infection
25 by M13-K07 (4×10^{10} pfu for 10 ml of early log culture) helper phage allowed packaging of the recombinant phagemid into phage-expressing antibody. The antigen-reactive phages were enriched through solid phase panning with GyrA coated plate. Briefly, microtiter wells (Nunc) coated with *M. smegmatis* GyrA (200 ng/well) were incubated with phages for 2 hours at 37°C. The unbound phages were washed thrice with 10 mM
30 phosphate buffer, followed by infection with TG1 cells. Infected TG-1 cells were plated on selection medium. Phages rescued from the individual plaques after biopanning were subsequently screened by ELISA using *M. smegmatis* GyrA bound microtitre plates with culture supernatants. Positive wells were detected with horseradish peroxidase conjugated anti-M13 antibody (Amersham pharmacia). The antigen positive clones were

rescued by helper phage infection and screened for binding by ELISA against *M. smegmatis* GyrA. The phages capable of binding *M. smegmatis* GyrA were used to infect *E. coli* HB2151 for generation of soluble scFv.

5 **E5 -Expression and detection of soluble scFv:**

HB2151 cells were infected with the recombinant antigen positive phages for soluble scFv production. Infected *E. coli* HB2151 cells grown to an A_{600} of 0.6 as per manufacturer's instructions and induced with 1 mM IPTG and grown at 25°C for 11 hours. The induced culture was pelleted down and the culture supernatant was filter
10 sterilized. The culture supernatant fractions were screened for the presence of scFv by ELISA against *M. smegmatis* GyrA bound microtitre plates and further detected with horseradish peroxidase conjugated anti-E tag antibody (Amersham Pharmacia Biotech).

EG -Purification of scFv fragment:

An anti-E tag antibody immunoaffinity column was prepared by amine coupling
15 to protein-G sepharose using dimethyl-pimilimidate (DMP). Briefly, 1.5 mg of anti-E-tag antibody was covalently coupled to 1.0 ml of protein-G sepharose using 20 mM DMP. After blocking and regeneration of the matrix, it was used for binding and purification of ScFv:GyrA. The 30-70% ammonium sulfate fraction from culture supernatant containing soluble scFv was dialyzed against PBS and loaded onto the anti-E tag column. After
20 washing the column with Glycine-HCl pH 5.0 buffer, scFv was eluted with Glycine-HCl pH 2.8. The eluted fractions were immediately neutralized with Tris-HCl pH 9.0. The fractions were further analyzed on 12% SDS-PAGE and followed by silver staining. The fractions containing scFv were pooled and dialyzed against Tris-KCl buffer (Tris-HCl 135 mM, 50 mM KCl and 10% Glycerol).

25

E7 -Kinetics of scFv:GyrA interaction with *M. smegmatis* GyrA and its comparison with IgG and Fab fragments:

Binding parameters were determined by Surface Plasmon Resonance (SPR) spectroscopy using a BIAcore 2000 system, Uppsala, Sweden. The over-expressed and
30 purified *M. smegmatis* GyrA was immobilized on the CM5 sensor chip at a concentration of 400 resonance units (RU) as per manufacturer's instructions. All measurements were carried out in a continuous flow of HBS buffer (10 mM HEPES, 150 mM NaCl, 5 mM EDTA and 0.05 % Surfactant P-20, pH 7.4) at 10 μ l/min. Purified MsGyrA:C3 IgG and its Fab and scFv:GyrA fragments were dialyzed against HBS buffer and used for

interaction studies. The kinetic data were analyzed using the BIA evaluation software (Version 3.0). The surface was regenerated by a pulse of 5 μ L of 100 mM NaOH, for further experimentation as required.

5 **ES -DNA and Protein sequencing analysis:**

Sequencing of the two independent scFv clones was carried out using 5' and 3' pCANTAB sequencing primers. The nucleotide sequence of two of the scFv:GyrA clones were translated to amino acid sequence and analyzed using DNA analysis program. The immunoglobulin sequence was further analyzed using Kabat database (E. A. Kabat et. al., Sequences of proteins of immunologic interest, United states Department of Health and Human services, Public health service, National institute of Health publication No. 37,1987) to define frame work and hypervariable regions. For N-terminal amino acid sequencing of MsGyrA:C3 κ chain, proteins were transferred onto an immobilon PVDF membrane (Millipore). The n-terminal amino acid sequence was determined by automated Edman degradation methodology and found to be IVMTQSPKS, confirming the authenticity of scFv sequence.

E9 -Experiment to show affinity of interaction and inhibition of DNA supercoiling activity by IgG, Fab and scFv are similar

In order to measure the affinity of interaction of scFv:GyrA and to compare it with C3:IgG and C3:Fab, surface plasmon resonance studies were carried out on GyrA immobilized surface. The scFv:GyrA interacted with *M. smegmatis* GyrA with an affinity of 2.17×10^{-10} M (Figure 4A), which is similar to its parent bivalent IgG (2.96×10^{-10} M) or monovalent Fab (1.68×10^{-10} M). This emphasizes that the engineering of two variable domains into a single polypeptide did not alter the affinity of interaction of antibody with its antigen.

To study the effect of scFv:GyrA interaction with GyrA on enzymatic activity, DNA supercoiling reactions were performed with *M. smegmatis* enzyme in presence of scFv:GyrA or parental IgG or Fab fragments. The enzyme was pre-incubated with soluble scFv, IgG or Fab to allow the formation of the antigen-antibody complex. The mixture was then added to relaxed pUC18 DNA, in the supercoiling reaction buffer. The results (Figure 4B) showed that mAb:C3 IgG, Fab and scFv fragments inhibited the mycobacterial DNA gyrase supercoiling activity to a similar extent. As compared to IgG, which is a 150 kDa protein with two antigen binding pockets, scFv is a monovalent 30

kDa polypeptide. The scFv fragments inhibited the supercoiling reaction at a concentration of 10-20 nM, which is in the same range as that of IgG or Fab. This indicates that inhibition is caused by direct interaction of the antigen binding site of the antibody with GyrA, rather than a result of a steric effect caused by the Fc regions of the immunoglobulins or by cross linking of adjacent GyrA molecules. DNA gyrase from
5 ofloxacin resistant, highly virulent clinical isolate of *M. tuberculosis* (ICC-222) was also completely inhibited by 10 nM scFv:GyrA (Figure 4C) like its parent IgG.

**E10 : Experiment to show the scFv:GyrA sequence and identification of
10 complementarity determining regions**

To characterize the structural features of MsGyrA:C3 responsible for their interactions with GyrA subunit, both heavy and light chain variable regions were sequenced (Seq. ID # 1 and 2). Comparison of the sequence with other known antibody sequences showed that V_H region of MsGyrA:C3 belongs to subgroup III_B according to
15 the classification of E. A. Kabat et. al., Sequences of proteins of immunologic interest, United states Department of Health and Human services, Public health service, National institute of Health publication No. **37, 1987**. Sequence analysis of V_L region suggest that it belongs to subgroup V. Based on the sequence analysis as defined by Kabat database the complementarity determining regions for light and heavy chain regions of scFv:GyrA
20 were identified and shown in bold letters in Seq. IDs # 1 and 2.

E11 : Experiment to show inhibition by paratope derived peptides

An antibody molecule binds specifically to its cognate antigen by synergistically using multiple non-covalent forces. The diversity of paratopes is mainly generated by
25 sequences present in the complementarity determining regions (CDR) of V_H (Variable heavy chain) and V_L, (Variable light chain) which are exposed hypervariable loop structures. Antigen binding by peptide sequences from selected CDRs of mAbs have been demonstrated to have specificity similar to those of the original antibody molecule. This section deals with rational design of biologically active peptides from the sequence
30 of scFv:GyrA with mycobacterial DNA gyrase inhibitory activity.

Based on variable sequence of scFv:GyrA, peptides corresponding to CDRs were synthesized and analyzed for DNA gyrase inhibition. We have identified a CDR:H1 sequence that specifically inhibits the DNA gyrase supercoiling activity. The results clearly indicate that the sequence **KASGYSFTVYYIYWVK** in CDR-H1 is a major part

of the discontinuous determinant involved in the antigen-antibody interaction. The complete inhibition of enzyme activity was observed at 5-10 μM peptide concentration in contrast to $>500 \mu\text{M}$ of CDR:H3 (Seq. IDs # 1 and 2). The results also suggest that other such inhibitory peptides could be designed using other CDR and framework region
5 sequence.

E12 - Experiment to show scFv:GyrA and the peptides derived from scFv inhibit ciprofloxacin resistant mycobacterial DNA gyrase

The experiments presented in this section of the invention address the inhibition
10 of quinolone resistant DNA gyrase activity by scFv:GyrA, CDR:H1 and CDR:H3 peptides. DNA gyrase from ciprofloxacin resistant (MIC_{50} 64 $\mu\text{g/ml}$) *M. smegmatis* mc²155 strain was used for the experiments. As expected, the enzyme showed resistance to ciprofloxacin (50 $\mu\text{g/ml}$) (Seq. ID # 1 and 2). However, DNA supercoiling activity was inhibited at 50 nM of scFv:GyrA and 10 μM CDR:H1 peptide (Seq. ID # 1 and 2).
15 Thus, the peptide inhibitor is equally effective against quinolone resistant DNA gyrase.


20

25

30

Claims

1. An engineered single chain antibody, which inhibits the activity of DNA gyrase from *M. smegmatis* and *M. tuberculosis*.
- 5 2. The engineered single chain antibody as claimed in claim 1 wherein it contains amino acid sequences for inhibiting the activity of DNA gyrase from *M. smegmatis* and *M. tuberculosis* said amino acid sequences having the Seq. ID # 3 and 4 respectively.
3. An engineered single chain antibody as claimed in Claim 1 wherein said antibody has
10 a nucleotide sequence shown in Seq. ID # 1.
4. An engineered single chain antibody as claimed in Claim 1 wherein said antibody has an amino acid sequence shown in Seq. ID # 2.
5. A peptide having an amino acid sequence as shown in Seq. ID # 2.
6. A process for the preparation of an engineered single chain antibody which inhibits
15 the activity of DNA gyrase from *M. smegmatis* and *M. tuberculosis*, said process comprising preparing complimentary DNA (cDNA) from the corresponding hybridoma cell lines which secretes monoclonal antibody, amplifying from said cDNA, DNA fragments encoding variable heavy chain region and light regions of said monoclonal antibody, fusing said variable heavy chain region and light regions
20 of said DNA fragments, cloning said fused DNA fragment in a plasmid, transforming said plasmid into *E. Coli* host strain, inducing said transformed cells to express said engineered single chain antibody and purifying said engineered single chain antibody from the induced cell lysate.
7. Monoclonal antibodies, which inhibit DNA gyrase from fluoroquinolone resistant *M. smegmatis* and *M. tuberculosis*.
25
8. A plasmid which inhibits the activity of DNA gyrase from *M. smegmatis* and *M. tuberculosis*, said plasmid being characterised in that it encodes an engineered single chain antibody containing amino acid sequences for inhibiting the activity of DNA gyrase from *M. smegmatis* and *M. tuberculosis* said amino acid sequences being as
30 shown in Seq. ID # 3 and 4 respectively.



B




Fig. 1






Fig. 2

A. *M. smegmatis* DNA gyrase



B. *M. smegmatis* DNA gyrase



D. Effect of MsGyrA:H11 on quinolone resistant *M. smegmatis* DNA gyrase

C. Ofloxacin resistant *M. tuberculosis* DNA gyrase





Fig. 3

A

	K_D (M)
IgG	2.96×10^{-10}
Fab	1.68×10^{-10}
scFv	2.17×10^{-10}





Fig. 4

5/7

1 - GCCCAGGTGAAACTGCAGCAGTCTGGGGCTGAATTGGTGAGGCCTGGGGCTTCAGTGAAG-60
 - A Q V K L Q Q S G A E L V R P G A S V K

61 - TTGTCCTGCAAGGCTTCTGGCTACAGCTTCACCGTCTACTATATTTACTGGGTGAAACAG -120
 - L S C K A S G Y S F T V Y Y I Y W V K Q

121- AGGCCTGGACAAGCCCTTGAGTGGATTGGAGAGATTAATCCTAGCAATGGTGGTACTAAC -180
 - R P G Q A L E W I G E I N P S N G G T N

181- TTCAATGAAAAGTTCAAGACCAAGGCCACACTGACTGTAGACAAATCCACCAGCACAGTC -240
 - F N E K F K T K A T L T V D K S T S T V

241- TACATGCAACTCAGCAGCCTGACATCTGAAGACTCTGCGGTCTATTACTGTACAAGATGG -300
 - Y M Q L S S L T S E D S A V Y Y C T R W

301- GGGTTACGACGAGGGTTTGCTTACTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAAGT -360
 - G L R R G F A Y W G Q G T T V T V S S S

361- GGAGCGGTTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACATCGAGCTCACTCAG -420
 - G G G S G G G G S G G G G S D I E L T Q

421- TCTCCAAAATCCATGTCCATGTCAGTAGGAGAGAGGGTACCTTGAGTTGC~~CAGT480
 - S P K S M S M S V G E R V T L S C K A S

481- GAGAATGTGCGTACTCATGTATCCTGGTATCAACAGAGACCAGAGGAGTCTCCTAAACTG-540
 - E N V G T H V S W Y Q Q R P E E S P K L

541- CTGATATACGGGGCATCCAACCCGTACACTGGGGTCCCCGATCGCTTCACAGGCAGTGGC -600
 - L I Y G A S N R Y T G V P D R F T G S G


601- TCTGCAACAGATTTCACTCTGACCATCAGCAATGTGCAGGCTGAAGACCTTGAGATTAT -660
 - S A T D F T L T I S N V Q A E D L A D Y

661- CACTGTGGACAGACTTACAGCTATCCATTACATTCGGCTTGGGGACAAAGTTGGAATA -720
 - H C G Q T Y S Y P F T F G L G T K L E I

721- AAACGGGCGGCCGAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCGCGTGCCGCA -780
 - K R A A A G A P V P Y P D P L E P R A A

781- TAG -783
 - *

Fig. 5



CDR:H1 - KASGYSFTVYYIYWVK
 CDR:H3 - TRWGLRRGFAYWGQ

Fig. 6




Fig. 7

SEQUENCE LISTING

<110> LUPIN LTD
 Nagaraja, Valakunja
 Manjunatha, Ujjini Havaladar
 Roy, Bhairab Nath

<120> PEPTIDE INHIBITORS FOR MYCOBACTERIAL DNA GYRASE

<130> HSM-LUP-GYR

<160> 4

<170> PatentIn version 3.1

<210> 1
 <211> 783
 <212> DNA
 <213> Escherichia coli and *Mus* sp.

<400> 1
 gccaggtga aactgcagca gtctggggct gaattggtga ggcctggggc ttcagtgaag 60
 ttgtctgca aggettctgg ctacagcttc accgtctact atatttactg ggtgaaacag 120
 aggctggac aagcccttga gtggattgga gagattaatc ctagcaatgg tggtaactaac 180
 ttcaatgaaa agttcaagac caaggccaca ctgactgtag acaaatccac cagcacagtc 240
 tacatgcaac tcagcagcct gacatctgaa gactctgceg tctattactg tacaagatgg 300
 gggttacgac gagggtttgc ttactggggc caagggacca cggtcaccgt ctcctcaagt 360
 ggaggcgggt caggcggagg tggctctggc ggtggcggat cggacatcga gctcactcag 420
 tctccaaaat ccatgtccat gtcagtagga gagagggtca ccttgagttg caaggccagt 480
 gagaatgtgg gtaactcatgt atcctggtat caacagagac cagaggagtc tectaaactg 540
 ctgatatacg gggcatccaa ccggtacact ggggtccccg atcgcttcac aggcagtggc 600
 tctgcaacag atttactct gaccatcagc aatgtgcagg ctgaagacct tgcagattat 660
 cactgtggac agacttacag ctatccattc acattcggct tggggacaaa gttggaata 720
 aaacgggcgg ccgaggtgc gccggtgccg tatccggatc cgctggaacc gcgtgccgca 780
 tag 783

<210> 2
 <211> 260
 <212> PRT
 <213> Escherichia coli and *Mus* sp.

<400> 2
 Ala Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly
 1 5 10 15
 Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Val
 20 25 30

<400> 3

Lys Ala Ser Gly Tyr Ser Phe Thr Val Tyr Tyr Ile Tyr Trp Val Lys
1 5 10 15

<210> 4

<211> 14

<212> PRT

<213> Escherichia coli and Mus sp.

<400> 4

Thr Arg Trp Gly Leu Arg Arg Gly Phe Ala Tyr Trp Gly Gln
1 5 10

Tyr Tyr Ile Tyr Trp Val Lys Gln Arg Pro Gly Gln Ala Leu Glu Trp
35 40 45

Ile Gly Glu Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys
50 55 60

Phe Lys Thr Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Val'
65 70 75 80

Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr
a5 90 95

Cys Thr Arg Trp Gly Leu Arg Arg Gly Phe Ala Tyr Trp Gly Gln Gly
100 105 110

Thr Thr Val Thr Val Ser Ser Ser Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125

Ser Gly Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Lys Ser
130 135 140

Met Ser Met Ser Val Gly Glu Arg Val Thr Leu Ser Cys Lys Ala Ser
145 150 155 160

Glu Asn Val Gly Thr His Val Ser Trp Tyr Gln Gln Arg Pro Glu Glu
165 170 175

Ser Pro Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val
180 185 190

Pro Asp Arg Phe Thr Gly Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr
195 200 205

Ile Ser Asn Val Gln Ala Glu Asp Leu Ala Asp Tyr His Cys Gly Gln
210 215 220

Thr Tyr Ser Tyr Pro Phe Thr Phe Gly Leu Gly Thr Lys Leu Glu Ile
225 230 235 240

Lys Arg Ala Ala Ala Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu Glu
245 250 255

Pro Arg Ala Ala
260

<210> 3
<211> 16
<212> PRT
<213> Escherichia coli and Mus sp.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IN J2/00192

4. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K16/12 C07K16/40 C07K7/08				
According to international Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, SEQUENCE SEARCH, BIOSIS, EMBASE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	MANJUNATHA, U. H. ET AL. : "Monoclonal antibodies to mycobacterial DNA gyrase A inhibit DNA supercoiling activity" EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 268, no. 7, April 2001 (2001-04), pages 2038-2046, XP002242358 cited in the application	6		
A	the whole document see especially: page 2045, column 1, line 42 - line 47 --- -/--	1-5, 7, 8		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.				
^o Special categories of cited documents : <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date '*L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) '*O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention '*X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone '*Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '*&' document member of the same patent family </td> </tr> </table>			'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date '*L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) '*O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed	'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention '*X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone '*Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '*&' document member of the same patent family
'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date '*L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) '*O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed	'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention '*X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone '*Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '*&' document member of the same patent family			
Date of the actual completion of the International search	Date of mailing of the international search report			
23 May 2003	10/06/2003			
Name and mailing address of the ISA	Authorized officer			
European Patent Office, P.B. 5818 Palentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Fuchs, U			

INTERNATIONAL SEARCH REPORT

Internationa	Application No
PCT/IN	02/00192

2.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	relevant to claim No.
A	NAGARAJA, V. ET AL. : "DNA Topoisomerase I from Mycobacteria - A Potential Drug Target" CURRENT PHARMACEUTICAL DESIGN, vol. 8, no. 22, August 2002 (2002-08), pages 1995-2007, XP008017418	1-8
A	the whole document see especially: page 2004, column 1, line 43 -column 2, line 53	
A	----- BINETRUY-TOURNAIRE, R. ET AL. : "Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis" EMBO JOURNAL, vol. 19, no. 7, 3 April 2000 (2000-04-03), pages 1525-1533, XP002242359 cited in the application the whole document -----	1-5,8

INTERNATIONAL SEARCH REPORT

In international application No.
PCT/IN 02/00192

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Present claims 1-4 relate to a single chain antibody defined by reference to a desirable characteristic or property, namely "which inhibits the activity of DNA gyrase from *M. smegmatis* and *M. tuberculosis*".

The claims cover all single chain antibodies having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such single chain antibodies. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the single chain antibody by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the single chain antibody containing amino acid sequences SEQ ID NOS: 3 and 4 or having amino acid sequence SEQ ID NO: 2 as disclosed in part E. of the description, pages 13-18.

The same applies to the monoclonal antibodies of claim 7 "which inhibit DNA gyrase from fluoroquinolone resistant *M. smegmatis* and *M. tuberculosis*". The search has been restricted to the monoclonal antibodies MsGyrA:C3 and MsGyrA:H11 disclosed in part D. of the description, pages 12-13, showing an inhibitory effect on DNA gyrase from fluoroquinolone resistant *M. smegmatis* and *M. tuberculosis*.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.